Close Menu

GenomeWeb

Verogen will gain access to GEDmatch's database of genetic profiles, although users can choose whether law enforcement can search their data to solve violent crimes.

An analysis found a 14 percent prevalence of germline cancer risk mutations and a 57 percent prevalence of variants of unknown significance.

Amgen's latest deal with a pharma company will see its clonoSeq assay used for minimal residual disease testing in a clinical trial for venetoclax.

The companies had agreed in early 2018 to collaborate on the development of technologies to support precision oncology initiatives, but Roche said "priorities" have changed.

Included in the deal is Diagnomics' minority stake in the Eone-Diagnomics Genome Center, a Korean provider of clinical and consumer genetics products and services.

Included in the deal is Diagnomics' minority stake in the Eone-Diagnomics Genome Center, a Korean provider of clinical and consumer genetics products and services.

The firm reported full year revenues of $54.4 million and fiscal Q4 revenues of $15.7 million, beating the consensus Wall Street estimates for both.

In a cartoon, Vox explores the lack of women among this year's winners of the Nobel Prize.

Science reports a new US defense bill would establish two groups aimed at combating foreign influence on research. 

Nature Biotechnology discusses promising early results from two clinical trials of CRISPR-based therapy for β-thalassemia and sickle cell disease.

In Cell this week: analysis of tissue clones, metagenomic studies of ocean water samples, and more.

Dec
06
Sponsored by
MNG Laboratories

Join MNG Laboratories' Chief Medical Officer, Dr. Peter L. Nagy, and the Clinical Reporting Team as they present multiple case studies illustrating the value of using complementary testing and data analysis methods to increase the clinical sensitivity of MNG’s genetic testing portfolio. The team will highlight cases solved through the application of high resolution CNV assessment, mitochondrial DNA analysis, transcriptome/RNA sequencing, and repeat expansion screening from genome sequencing datasets. After the presentation, there will be a 15 minute Q&A with our speakers. 

Oct
25
Sponsored by
MNG Laboratories

Join us for a webinar presented by our Chief Medical Officer, Dr. Peter L. Nagy, to discuss the benefits of performing and analyzing genome and RNA sequencing together. The increased number of single nucleotide and copy number variants associated with genome sequencing are best interpreted with the help of joint parental testing and the assessment of the functional significance of intronic and regulatory changes with a functional test like the transcriptome.